Related Experiment Videos
Cyclooxygenase inhibitors: any reservations?
P S Penglis1, M J James, L G Cleland
1Rheumatology Unit, Royal Adelaide Hospital, South Australia. peter.penglis@student.adelaide.edu.au
Internal Medicine Journal
|August 2, 2001
Summary
Selective COX-2 inhibitors offer anti-inflammatory benefits with fewer gastric issues than traditional NSAIDs. However, the COX-1/COX-2 paradigm is complex, necessitating ongoing surveillance for other potential adverse effects.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Development
Background:
- Discovery of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isozymes.
- Development of selective COX-2 inhibitors (e.g., celecoxib, rofecoxib) based on the COX-1 constitutive/COX-2 inflammatory paradigm.
- Traditional non-steroidal anti-inflammatory drugs (NSAIDs) inhibit both COX-1 and COX-2, leading to gastrointestinal side effects.
Purpose of the Study:
- To evaluate the benefits and risks of selective COX-2 inhibitors.
- To examine the validity of the distinct roles of COX-1 and COX-2.
- To highlight the need for post-marketing surveillance of selective COX-2 inhibitors.
Main Methods:
- Review of existing literature on COX isozymes and selective inhibitors.
- Analysis of clinical data regarding gastrointestinal and other adverse events.
- Pharmacological assessment of eicosanoid profile changes.
Main Results:
- Selective COX-2 inhibitors provide anti-inflammatory effects with reduced gastric adverse events compared to traditional NSAIDs.
- Evidence suggests the COX-1/COX-2 paradigm is not strictly defined.
- Selective COX-2 inhibitors can alter the eicosanoid profile, potentially leading to other adverse effects.
Conclusions:
- Selective COX-2 inhibitors offer a safer gastrointestinal profile.
- The 'COX-1 constitutive, COX-2 inflammatory' model requires further refinement.
- Vigilant post-marketing surveillance is crucial for identifying unforeseen adverse effects of selective COX-2 inhibitors.